CancerTYPE ID Study Underscores Value of Knowing Tissue of Origin Amid Tissue-Agnostic Approvals
The use of BRAF inhibitors in patients with BRAF V600E mutations without identification of site of origin in CUP patients can lead to inappropriate therapy.
Source: precisiononcologynews.com